Summary of the results from reduced-intensity conditioning regimens with and without immunosuppression
| Conditioning agent(s) . | Sca-1+ cell dose . | Immunosuppression . | Percent chimerism . | FVIII activity, U/mL . |
|---|---|---|---|---|
| BU, 35 mg/kg | 300 000 | none | 0 | 0 |
| BU, 35 mg/kg and CY, 200 mg/kg | 300 000 | none | 0 | 0 |
| BU, 35 mg/kg | 300 000 | Anti-CD40L + CTLA4Ig | 29.6 ± 18.1 | 0.12 ± 0.19 |
| BU, 20 mg/kg | 300 000 | ATS | 7.6 ± 9.6 | 0.01 ± 0.01 |
| BU, 20 mg/kg | 1 000 000 | ATS | 27.2 ± 18.6 | 2.66 ± 1.96 |
| BU, 35 mg/kg | 300 000 | ATS | 41.1 ± 25.5 | 4.04 ± 1.66 |
| BU, 35 mg/kg | 1 000 000 | ATS | 18.5 ± 13.6 | 3.44 ± 2.07 |
| TBI, 3 Gy | 300 000 | none | 0 | 0 |
| TBI, 3 Gy | 300 000 | ATS | 17.4 ± 7.3 | 2.05 ± 0.87 |
| TBI, 3 Gy | 1 000 000 | ATS | 53.8 ± 15.2 | 3.73 ± 1.08 |
| Conditioning agent(s) . | Sca-1+ cell dose . | Immunosuppression . | Percent chimerism . | FVIII activity, U/mL . |
|---|---|---|---|---|
| BU, 35 mg/kg | 300 000 | none | 0 | 0 |
| BU, 35 mg/kg and CY, 200 mg/kg | 300 000 | none | 0 | 0 |
| BU, 35 mg/kg | 300 000 | Anti-CD40L + CTLA4Ig | 29.6 ± 18.1 | 0.12 ± 0.19 |
| BU, 20 mg/kg | 300 000 | ATS | 7.6 ± 9.6 | 0.01 ± 0.01 |
| BU, 20 mg/kg | 1 000 000 | ATS | 27.2 ± 18.6 | 2.66 ± 1.96 |
| BU, 35 mg/kg | 300 000 | ATS | 41.1 ± 25.5 | 4.04 ± 1.66 |
| BU, 35 mg/kg | 1 000 000 | ATS | 18.5 ± 13.6 | 3.44 ± 2.07 |
| TBI, 3 Gy | 300 000 | none | 0 | 0 |
| TBI, 3 Gy | 300 000 | ATS | 17.4 ± 7.3 | 2.05 ± 0.87 |
| TBI, 3 Gy | 1 000 000 | ATS | 53.8 ± 15.2 | 3.73 ± 1.08 |
Data shown are from 14 to 16 weeks after transplantation.